KCS Corneal Ulcers in Dogs: Treatment That Works

A Shih-Tzu presents with acute blepharospasm and a mucopurulent discharge. Fluorescein staining confirms a superficial corneal ulcer. Antibiotics are dispensed. At the two-week recheck, the ulcer looks exactly the same. Another course of antibiotics. At week four, still no improvement. The owner is frustrated. You’re treating the ulcer — but not the wound environment that’s preventing it from healing.

Keratoconjunctivitis sicca is one of the most common ophthalmic diagnoses in small animal practice, and corneal ulceration is one of its most serious consequences. A 2023 AVMA study found that 68% of dogs with documented KCS had a concurrent corneal ulcer. The connection isn’t incidental — it’s mechanistic. And the management failure pattern described above happens precisely because the ulcer and the tear deficiency are treated as separate problems rather than as one.

Why Does KCS Cause Corneal Ulcers — and Why Do They Keep Coming Back?

The corneal epithelium is avascular. It has no direct blood supply and depends entirely on the tear film for oxygen delivery, nutrient transport, and the growth factors that maintain epithelial homeostasis between injuries. Normal tear film isn’t just lubrication — it’s a biochemically active environment containing EGF, HGF, KGF, IGF-1, TGF-β, and nerve growth factor, all of which coordinate epithelial maintenance and repair.

Immune-mediated KCS — the most common form in dogs — destroys the lacrimal gland’s secretory capacity through T-cell-mediated infiltration. As tear production falls below protective thresholds, the cascade follows a predictable course: conjunctival hyperemia and mucoid discharge, followed by epithelial desiccation, then hyperplasia and corneal vascularization, and eventually ulceration. Reduced tear flow doesn’t just dry the cornea — it strips away the growth factor environment that the epithelium depends on to repair itself. The ulcer can’t close because the biological signals for closure are no longer present at adequate concentrations.

Secondary bacterial infection and protease-mediated keratomalacia accelerate this process, particularly in cases where the underlying tear deficiency goes unrecognized. A superficial ulcer in a KCS-affected eye faces a fundamentally different healing environment than the same ulcer in a healthy eye — and treating it the same way produces the frustrating result described above.

Four breeds account for 58% of KCS cases in referral populations: English Cocker Spaniels, Cavalier King Charles Spaniels, West Highland White Terriers, and Shih-Tzus. Cavalier King Charles Spaniels and Shih-Tzus show a particularly aggressive disease pattern, with significantly higher rates of ulcerative keratitis and documented cases progressing to corneal perforation. Brachycephalic breeds face compounded risk: KCS prevalence is elevated, and when ulceration occurs, the corneal surface geometry and exposure increase the likelihood of deeper involvement. Any ulcer in a breed from this list should trigger immediate Schirmer tear test measurement at the first presentation.

What Schirmer Tear Test Values Should Change Your Treatment Plan?

The Schirmer tear test is the definitive diagnostic tool, and specific thresholds carry clinical weight that should directly govern treatment decisions:

Greater than 15 mm/min: Normal. Tear deficiency is not the cause of a non-healing ulcer in these patients.
10–15 mm/min: Borderline. Tear film is compromised; early KCS cannot be excluded. Treat the ulcer and retest in 3–4 weeks.
Less than 15 mm/min: Diagnostic for KCS. Initiate immunotherapy alongside ulcer management.
Less than 10 mm/min: Clinically significant disease. Corneal surface is compromised; the healing environment is pathological. Immunotherapy is urgent.
Less than 2 mm/min: Severe disease. Cyclosporine response rate drops to approximately 50%, and prognosis for full tear production recovery is guarded. Tacrolimus should be considered first-line.

Tear film breakup time (TBUT) provides a complementary picture: normal is 20 seconds or more; less than 5 seconds indicates qualitative tear film instability even when volume is near-normal. A patient with an STT of 12 mm/min and a TBUT of 3 seconds has a tear film that can’t maintain surface coverage, and a corneal ulcer in that environment is working against the same growth factor deficit seen in more severe disease.

The clinical implication: STT measurement should not wait until antibiotics fail. If a corneal ulcer is present in a breed at risk for KCS, run the STT at the first appointment.

What Cyclosporine and Tacrolimus Can — and Cannot — Do for the Corneal Surface

Topical cyclosporine A (0.2%) is the standard of care for immune-mediated KCS. It works by blocking IL-2-mediated T-cell proliferation in the lacrimal gland, allowing secretory capacity to recover. It improves STT values in approximately 81.8% of cases and is the correct primary treatment for the underlying disease.

But cyclosporine treats the immunopathology, not the corneal surface — and there is a lag between initiating treatment and meaningful tear production recovery. That lag is typically four to eight weeks. During this period, the corneal epithelium is still desiccated, still growth factor-depleted, and still operating in a wound environment that cannot support normal healing. A 2021 study demonstrated that 45 days of topical cyclosporine does not normalize the tear protein profile: lysozyme remains reduced, and while inflammatory markers improve, the biochemical composition of the tear film does not recover to normal within the treatment window that matters most for ulcer closure.

Tacrolimus (0.03%) is reserved for cyclosporine-unresponsive cases and carries a more potent but similar immunosuppressive mechanism. Pilocarpine is appropriate only for neurogenic KCS confirmed by ipsilateral dry nose and reduced STT — it has no role in immune-mediated disease.

What this means in practice: starting cyclosporine is necessary and correct. But it does not rescue the corneal surface in the weeks it takes to work. The ulcer is healing — or failing to heal — during exactly that window.

Why Growth Factor Support Belongs in the Protocol Before the Ulcer Heals

The KCS corneal ulcer is not a wound problem. It is a wound environment problem. The cornea has the cellular machinery to repair itself, but the biochemical signals it needs — particularly EGF, HGF, and KGF — are not present at therapeutic concentrations in the KCS tear film. Research has confirmed that EGF release rates are significantly lower in eyes with ocular surface disease compared to normal eyes during reflex tearing. The signal that tells corneal epithelial cells to migrate, proliferate, and differentiate is simply not there at the level needed to drive closure.

Amniotic eye drops deliver that signal exogenously. Measured growth factor concentrations in amniotic membrane preparations include EGF (41 pg/mL), fibroblast growth factor (43 pg/mL), HGF (204 pg/mL), KGF (328 pg/mL), and nerve growth factor (208 pg/mL) — the same growth factors the KCS tear film is failing to provide. Applied topically, these support corneal epithelial cell migration and proliferation, reduce inflammation at the wound margin, and address the growth factor deficit that cyclosporine cannot fill while it’s working on the lacrimal gland.

This is the role EyeQ plays in the KCS management protocol — not as a treatment for KCS, and not as a replacement for cyclosporine, but as targeted surface support during the lag phase and beyond. While immunotherapy rebuilds tear production over weeks, EyeQ supplements the depleted growth factor environment at the corneal surface where the ulcer needs to close now.

The three clinical scenarios where this matters most:

New KCS diagnosis with concurrent ulcer. The patient who presents with both problems simultaneously. Cyclosporine must start for the underlying disease, but it cannot help the corneal surface for four to eight weeks. Growth factor supplementation addresses the surface while immunotherapy addresses the cause.

The “controlled” KCS patient whose ulcer still won’t close. STT at 11 mm/min after months of cyclosporine — improved, but still below the 15 mm/min threshold for full epithelial support. The tear film is not normalized. The corneal ulcer in this patient is operating in a growth factor-depleted environment, not a healthy one.

The ulcer in a high-risk breed that triggers the STT. Brachycephalic and breed-specific risk profiles mean the index of suspicion for concurrent KCS should be high from the first visit. Running STT at presentation — and layering growth factor support into the protocol from day one — changes the trajectory before the four-week recheck produces no improvement.

The rationale for including EyeQ in the KCS-associated ulcer protocol isn’t complicated: cyclosporine restores tear production over time, and EyeQ provides the growth factor environment the corneal surface needs while it waits. Trusted by over 90% of veterinary ophthalmologists and used in over 100,000 eyes, EyeQ is the tool ophthalmologists reach for when the corneal surface needs more than antibiotics and lubricants can provide.

Learn more about EyeQ and how it supports corneal healing at RethinkHealing.com.

When Dry Eye Causes Corneal Ulcers in Dogs

Why Does KCS Cause Corneal Ulcers — and Why Do They Keep Coming Back?

What Schirmer Tear Test Values Should Change Your Treatment Plan?

What Cyclosporine and Tacrolimus Can — and Cannot — Do for the Corneal Surface

Why Growth Factor Support Belongs in the Protocol Before the Ulcer Heals

Sources

Vetrix

Office Hours